Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.43 |
| ▸ | PARP1 | P09874 | 7/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hypoxanthine SCHEMBL30266940 | 0.98 | TSHR (0.45) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| Hypoxanthine SCHEMBL29467372 | 0.84 | CYP1A2 (0.41) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| Hypoxanthine SCHEMBL30324467 | 0.84 | CYP1A2 (0.41) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| Hypoxanthine SCHEMBL29533161 | 0.82 | TSHR (0.41) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| Hypoxanthine SCHEMBL31181347 | 0.82 | ACHE (0.38) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| SCHEMBL6379644 | 0.76 | ALDH1A1 (0.53) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| SCHEMBL14094281 | 0.73 | SMN1; SMN2 (0.46) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| SCHEMBL5526644 | 0.73 | ALDH1A1 (0.40) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| SCHEMBL440223 | 0.72 | SMN1; SMN2 (0.40) | TSHRSMN1; SMN2LMNAADORA2ASLC6A4 | |
| SCHEMBL21440777 | 0.71 | ALDH1A1 (0.54) | RAB9AALDH1A1ACHEGDAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| US-20240343754-A1 | 7-SUBSTITUTED 7-DEAZAADENINE-CONTAINING 2',3'-CYCLIC DINUCLEOTIDES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2024-10-17 | — | — | US | claimed |
| EP-4387978-A1 | 7-SUBSTITUTED 7-DEAZAADENINE-CONTAINING 2',3'-CYCLIC DINUCLEOTIDES | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) | 2024-06-26 | — | — | EP | claimed |
| CN-110997691-B | Cyclic dinucleotides as anticancer agents | 百时美施贵宝公司 | 2023-11-07 | — | — | CN | claimed |
| WO-2023020640-A1 | 7-SUBSTITUTED 7-DEAZAADENINE-CONTAINING 2',3'-CYCLIC DINUCLEOTIDES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I. (CZ) | 2023-02-23 | — | — | WO | claimed |
| EP-4137499-A1 | 7-SUBSTITUTED 7-DEAZAADENINE-CONTAINING 2,3 -CYCLIC DINUCLEOTIDES | Ustav organicke chemie a biochemie AV CR, v.v.i. (CZ) | 2023-02-22 | — | — | EP | claimed |
| EP-3658565-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-09 | — | — | EP | claimed |
| CN-114981999-A | Surface modified carbon based electrode for electrochemical capacitors | EEXION能源有限公司 | 2022-08-30 | — | — | CN | claimed |
| WO-2022065413-A1 | NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF | 株式会社理研ジェネシス | 2022-03-31 | — | — | WO | claimed |
| EP-1608317-A4 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2006-12-27 | — | — | EP | claimed |
| EP-1608317-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-01-06 | — | — | US | claimed |
| US-20040259870-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-23 | — | — | US | claimed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | claimed |
| EP-0304004-A1 | Process for the production of sodium purines | BOEHRINGER INGELHEIM KG (DE) | 1989-02-22 | — | — | EP | claimed |
| US-20260146992-A1 | INTESTINAL BIOMARKERS FOR GUT HEALTH IN DOMESTICATED BIRDS | INTERNATIONAL N&H DENMARK APS (DK) | 2026-05-28 | — | — | US | disclosed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-4430495-A | Process for preparing lincomycin and clindamycin ribonucleotides | THE UPJOHN COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | TSHR 729/4885SMN1; SMN2 3765/4885LMNA 4633/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | TSHR 2503/4885SMN1; SMN2 1863/4885LMNA 1269/4885 |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | TSHR 442/4885SMN1; SMN2 4426/4885LMNA 4485/4885 |
| US-20040259870-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | TSHR 453/4885SMN1; SMN2 4500/4885LMNA 4553/4885 |
| US-20260146992-A1 | INTESTINAL BIOMARKERS FOR GUT HEALTH IN DOMESTICATED BIRDS | FABP2, AADAT, HNMT | TSHR 3833/4885SMN1; SMN2 4602/4885LMNA 469/4885 |
| US-20240343754-A1 | 7-SUBSTITUTED 7-DEAZAADENINE-CONTAINING 2',3'-CYCLIC DINUCLEOTIDES | STING1, CGAS, IRF3 | TSHR 3128/4885SMN1; SMN2 4067/4885LMNA 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.